Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma

Roche announced today that the European Commission has approved Gazyvaro ® (obinutuzumab) in combination with chemotherapy, followed by Gazyvaro maintenance in people achieving a response, as a new treatment for previously untreated advanced follicular lymphoma.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news